Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PTCL Clear all
Recruiting Phase 3 Interventional

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

NCT06724237
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
Procedure · Other · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
164
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

NCT05239910
View directory record Official record
Conditions
Peripheral T Cell Lymphoma
Interventions
Tenalisib
Drug
Lead sponsor
Rhizen Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Phase 1 Interventional

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

NCT02978235
View directory record Official record
Conditions
Multiple Myeloma, NonHodgkin Lymphoma
Interventions
TAS4464
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Bethesda, Maryland • Boston, Massachusetts • Farmington Hills, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

NCT02362997
View directory record Official record
Conditions
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
6
States / cities
Duarte, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT06137144
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL
Interventions
AZD3470, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Results available

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

NCT02689453
View directory record Official record
Conditions
T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T Cell Lymphoma (CTCL), T-Cell Prolymphocytic Leukemia
Interventions
IL-15 plus, alemtuzumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 10, 2026, 4:41 PM EDT
Withdrawn Phase 1Phase 2 Interventional

PLM60 for Peripheral T Cell Lymphoma (PTCL)

NCT03553914
View directory record Official record
Conditions
Peripheral T Cell Lymphoma
Interventions
PLM60
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT02232516
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome
Interventions
romidepsin, lenalidomide, laboratory biomarker analysis
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

NCT02495415
View directory record Official record
Conditions
Peripheral T-cell Lymphoma
Interventions
Fenretinide
Drug
Lead sponsor
CerRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
11
States / cities
Gilbert, Arizona • Los Angeles, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

NCT03192202
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous
Interventions
AFM13
Drug
Lead sponsor
Ahmed Sawas
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 10, 2026, 4:41 PM EDT
Withdrawn Phase 2 Interventional

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

NCT04795869
View directory record Official record
Conditions
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions
Brentuximab Vedotin, Pembrolizumab
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

NCT00888927
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma
Interventions
KW-0761
Biological
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

NCT02142530
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Peripheral T-cell Lymphoma
Interventions
Carfilzomib, Belinostat
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

NCT02440685
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Cancer, Neoplasm, Tumor, Lymphoma, Malignant, Lymphoma, B-cell, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, B-Cell Leukemia, Chronic, B-Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Chronic, B Cell, Myelofibrosis, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, Lymphoma, T Cell, Peripheral, Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Peripheral
Interventions
ASN002 Dose Escalation, ASN002 RD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Tempe, Arizona • San Francisco, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

NCT05475925
View directory record Official record
Conditions
LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Extranodal NK/T Cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker), Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)
Interventions
DR-01
Drug
Lead sponsor
Dren Bio
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

NCT05225584
View directory record Official record
Conditions
Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors
Interventions
KT-333
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Orange, California • Louisville, Kentucky • Detroit, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

NCT05140382
View directory record Official record
Conditions
Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma
Interventions
AZD4573
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Boston, Massachusetts • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

NCT00787527
View directory record Official record
Conditions
Lymphoma
Interventions
Zolinza (vorinostat), Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

NCT03161223
View directory record Official record
Conditions
Lymphoma, T-Cell
Interventions
Durvalumab, Pralatrexate, Romidepsin, 5-Azacitidine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 10, 2026, 4:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

NCT03547700
View directory record Official record
Conditions
Lymphoma, T-Cell, Peripheral
Interventions
Romidepsin, Ixazomib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT03372057
View directory record Official record
Conditions
Peripheral T-cell Lymphoma
Interventions
Duvelisib
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
19
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 10, 2026, 4:41 PM EDT
Recruiting Phase 3 Interventional

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

NCT06072131
View directory record Official record
Conditions
Peripheral T Cell Lymphoma
Interventions
Belinostat Injection, Pralatrexate Injection, CHOP, COP
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
11
States / cities
Clovis, California • Santa Monica, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 10, 2026, 4:41 PM EDT
Suspended Phase 1Phase 2 Interventional

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

NCT05138458
View directory record Official record
Conditions
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy, Cell Therapy
Interventions
MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy
Biological · Other
Lead sponsor
Myeloid Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Duarte, California • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 10, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

NCT02512497
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia, T-Lymphoblastic Leukemia/Lymphoma, Peripheral T-Cell Lymphoma
Interventions
Romidepsin, Busulfan, Fludarabine, Stem Cell Transplant, Thymoglobulin
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 10, 2026, 4:41 PM EDT